N-3 polyunsaturated fatty acids prevent the defect of insulin receptor signaling in muscle

Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E664-71. doi: 10.1152/ajpendo.00320.2001.

Abstract

A high-fat diet containing polyunsaturated fatty acids (PUFA: n-3 or n-6) given for 4 wk to 5-wk-old male Wistar rats induced a clear hyperglycemia (10.4 +/- 0.001 mmol/l for n-6 rats and 10.1 +/- 0.001 for n-3 rats) and hyperinsulinemia (6.6 +/- 0.8 ng/ml for n-6 rats and 6.4 +/- 1.3 for n-3 rats), signs of insulin resistance. In liver, both diets (n-3 and n-6) significantly reduced insulin receptor (IR) number, IR and IR substrate (IRS)-1 tyrosine phosphorylation, and phosphatidylinositol (PI) 3'-kinase activity. In contrast, in leg muscle, IR density, as determined by Western blotting, was not affected, whereas IR and IRS-1 tyrosine phosphorylation in response to insulin treatment was restored in animals fed with n-3 PUFA to normal; in n-6 PUFA, the phosphorylation was depressed, as evidenced by Western blot analysis using specific antibodies. In addition, PI 3'-kinase activity and GLUT-4 content in muscle were maintained at normal levels in rats fed with n-3 PUFA compared with rats fed a normal diet. In rats fed with n-6 PUFA, both PI 3'-kinase activity and GLUT-4 content were reduced. Furthermore, in adipose tissue and using RT-PCR, we show that both n-3 and n-6 PUFA led to slight or strong reductions in p85 expression, respectively, whereas GLUT-4 and leptin expression was depressed in n-6 rats. The expression was not affected in n-3 rats compared with control rats. In conclusion, a high-fat diet enriched in n-3 fatty acids maintained IR, IRS-1 tyrosine phosphorylation, and PI 3'-kinase activity and total GLUT-44 content in muscle but not in liver. A high-fat diet (n-3) partially altered the expression of p85 but not that of GLUT-4 and leptin mRNAs in adipose tissue.

MeSH terms

  • Adipose Tissue / chemistry
  • Animals
  • Blood Glucose / analysis
  • Dietary Fats / administration & dosage
  • Dietary Fats / pharmacology*
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / analysis
  • Fatty Acids, Omega-3 / pharmacology*
  • Fatty Acids, Omega-6
  • Fatty Acids, Unsaturated / administration & dosage
  • Fatty Acids, Unsaturated / analysis
  • Fatty Acids, Unsaturated / pharmacology
  • Glucose Transporter Type 4
  • Insulin / blood
  • Insulin / metabolism
  • Insulin / pharmacology
  • Insulin Receptor Substrate Proteins
  • Insulin Resistance
  • Leptin / genetics
  • Leptin / metabolism
  • Lipids / analysis
  • Liver / chemistry
  • Liver / metabolism
  • Male
  • Monosaccharide Transport Proteins / genetics
  • Muscle Proteins*
  • Muscle, Skeletal / chemistry
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / metabolism*
  • Phosphatidylinositol 3-Kinases / genetics
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphoproteins / genetics
  • Phosphoproteins / metabolism
  • Phosphorylation
  • Phosphotyrosine / metabolism
  • RNA, Messenger / analysis
  • Rats
  • Rats, Wistar
  • Receptor, Insulin / drug effects
  • Receptor, Insulin / genetics
  • Receptor, Insulin / physiology*
  • Signal Transduction*

Substances

  • Blood Glucose
  • Dietary Fats
  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • Fatty Acids, Unsaturated
  • Glucose Transporter Type 4
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Irs1 protein, rat
  • Leptin
  • Lipids
  • Monosaccharide Transport Proteins
  • Muscle Proteins
  • Phosphoproteins
  • RNA, Messenger
  • Slc2a4 protein, rat
  • Phosphotyrosine
  • Phosphatidylinositol 3-Kinases
  • Receptor, Insulin